WO2006105319A3 - Assessment of cardiac disease by cec gene profile analysis - Google Patents

Assessment of cardiac disease by cec gene profile analysis Download PDF

Info

Publication number
WO2006105319A3
WO2006105319A3 PCT/US2006/011691 US2006011691W WO2006105319A3 WO 2006105319 A3 WO2006105319 A3 WO 2006105319A3 US 2006011691 W US2006011691 W US 2006011691W WO 2006105319 A3 WO2006105319 A3 WO 2006105319A3
Authority
WO
WIPO (PCT)
Prior art keywords
cec
binding protein
assessment
provides
disease
Prior art date
Application number
PCT/US2006/011691
Other languages
French (fr)
Other versions
WO2006105319A2 (en
Inventor
Shawn Mark O'hara
Denis Smimov
Original Assignee
Immunivest Corp
Shawn Mark O'hara
Denis Smimov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunivest Corp, Shawn Mark O'hara, Denis Smimov filed Critical Immunivest Corp
Publication of WO2006105319A2 publication Critical patent/WO2006105319A2/en
Publication of WO2006105319A3 publication Critical patent/WO2006105319A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Abstract

bstract Elevated number of Circulating Endothelial Cells (CEC) have been implicated in disease conditions associated with the formation or destruction of blood vessels such as acute coronary syndrome, thrombocytopenic purpura, sickle cell disease, sepsis, lupus, nephrotic syndromes, rejection of organ transplants, surgical trauma and cancer. This invention provides a method for assessing the levels of CEC which vary between different studies using a sensitive enrichment, imaging, and enumberation analysis. Neuroligin, GATA binding protein 4, and fatty acid binding protein are found in CEC populations, yet are in trace amounts in the white blood cell population. This provides a method for diagnosing and finding the organ of origin in cardiovascular disease states.
PCT/US2006/011691 2005-03-30 2006-03-30 Assessment of cardiac disease by cec gene profile analysis WO2006105319A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59433805P 2005-03-30 2005-03-30
US60/594,338 2005-03-30
US59446105P 2005-04-11 2005-04-11
US60/594,461 2005-04-11

Publications (2)

Publication Number Publication Date
WO2006105319A2 WO2006105319A2 (en) 2006-10-05
WO2006105319A3 true WO2006105319A3 (en) 2007-04-05

Family

ID=37054136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/011691 WO2006105319A2 (en) 2005-03-30 2006-03-30 Assessment of cardiac disease by cec gene profile analysis

Country Status (1)

Country Link
WO (1) WO2006105319A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2229441B1 (en) 2007-12-12 2014-10-01 The Board of Trustees of The Leland Stanford Junior University Method and apparatus for magnetic separation of cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051344A1 (en) * 1994-06-17 2001-12-13 Shalon Tidhar Dari Methods for constructing subarrays and uses thereof
WO2006020936A2 (en) * 2004-08-12 2006-02-23 Immunivest Corporation A method for assessing disease states by profile analysis of isolated circulating endothelial cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051344A1 (en) * 1994-06-17 2001-12-13 Shalon Tidhar Dari Methods for constructing subarrays and uses thereof
WO2006020936A2 (en) * 2004-08-12 2006-02-23 Immunivest Corporation A method for assessing disease states by profile analysis of isolated circulating endothelial cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SMIRNOV D.A. ET AL.: "Global Gene Expression Profiling of Circulating Endothelial Cells in Patients with Metastatic Carcinomas", CANCER RESEARCH, vol. 66, no. 6, 15 March 2006 (2006-03-15), pages 2918 - 2922, XP003009584 *

Also Published As

Publication number Publication date
WO2006105319A2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
Tester et al. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice
Nivard et al. Genetic overlap between schizophrenia and developmental psychopathology: longitudinal and multivariate polygenic risk prediction of common psychiatric traits during development
Jantos-Siwy et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease
Weder Evolution and hypertension
Poninska et al. Next-generation sequencing for diagnosis of thoracic aortic aneurysms and dissections: diagnostic yield, novel mutations and genotype phenotype correlations
Pilkerton et al. Changes in cardiovascular health in the United States, 2003–2011
Shah et al. Circulating cytokines after hip and knee arthroplasty: a preliminary study
Blankenburg et al. β-Myosin heavy chain variant Val606Met causes very mild hypertrophic cardiomyopathy in mice, but exacerbates HCM phenotypes in mice carrying other HCM mutations
Tayal et al. Understanding the genetics of adult-onset dilated cardiomyopathy: what a clinician needs to know
Ghisletta et al. The Val/Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene predicts decline in perceptual speed in older adults.
Souissi et al. Genomic and geographic footprints of differential introgression between two divergent fish species (Solea spp.)
Long et al. Exome sequencing identifies pathogenic and modifier mutations in a child with sporadic dilated cardiomyopathy
LeDuc et al. Novel association of early onset hepatocellular carcinoma with transaldolase deficiency
EP3428649A3 (en) Identification of patients with abnormal fractional shortening
Bartling et al. Altered gene expression pattern indicates the differential regulation of the immune response system as an important factor in cardiac aging
WO2006020936A3 (en) A method for assessing disease states by profile analysis of isolated circulating endothelial cells
Talenti et al. A method for single nucleotide polymorphism selection for parentage assessment in goats
Gellersen et al. Memory precision of object-location binding is unimpaired in APOE ε4-carriers with spatial navigation deficits
Yücel et al. Evaluation of atherogenic laboratory markers in Behçet’s disease patients with vascular involvement
EP3968340A1 (en) Device and method for predicting risk for disease combined with genetic risk for associated phenotype
Cabrera-Serrano et al. Bi-allelic loss-of-function OBSCN variants predispose individuals to severe recurrent rhabdomyolysis
WO2006105319A3 (en) Assessment of cardiac disease by cec gene profile analysis
EP2770066A3 (en) Compositions and methods for detecting mutations in JAK2 nucleic acid
Kirk et al. Quantitative trait loci modifying cardiac atrial septal morphology and risk of patent foramen ovale in the mouse
Arpegård et al. Cystatin C predicts incident cardiovascular disease in twins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06748950

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)